The stigma associated with the autoimmune disease psoriasis may lead people to avoid patients who show signs of the condition, including not wanting to date, shake hands, or have people in their homes if they suffer from the disease. New multidisciplinary research involving both psychologists and dermatologists is the first to examine how common this stigma may be among the general population of the United States as well as among medical students.
Research has shown that targeting metabolism in growing cells holds promise for the treatment of skin diseases like psoriasis that are characterized by skin overgrowth resulting from excess cell division, known as hyperproliferation.
A compound from the body's own immune cells can treat psoriasis in mice and holds promise for other autoimmune diseases such as multiple sclerosis, according to a new study.
An antibody used to treat the skin disease psoriasis is also effective at reducing aortic inflammation, a key marker of future risk of major cardiovascular events.
An international team of researchers has unraveled a crucial aspect of the molecular basis of autoimmune and inflammatory diseases such as psoriasis, rheumatoid arthritis and Crohn's disease. Focusing on the immunomodulatory cytokine IL-23 they discovered that its pro-inflammatory activity, which underlies a wide range of inflammatory diseases, critically depends on structural activation of the cytokine by its receptor, IL-23R.
Small amounts of artificial vanilla extract, also known as vanillin, are in a wide range of products, from baked goods to perfumes. But vanillin's versatility doesn't stop there. In a recent mouse study researchers report that this compound could also prevent or reduce psoriatic skin inflammation.
People with psoriasis are at a higher risk to develop type 2 diabetes than those without psoriasis, and the risk increases dramatically based on the severity of the disease. Researchers found people with psoriasis that covers 10 percent of their body or more are 64 percent more likely to develop diabetes than those without psoriasis, independent of traditional risk factors such as body weight.
Researchers report the discovery of a key underlying immune mechanism that explains why to how our skin becomes inflamed from conditions such as atopic dermatitis, more commonly known as eczema. Toxin-producing bacteria on the surface of our skin induces a protein that causes our own cells to react and cause inflammation.
Stem cells in the skin remember an injury, helping them close recurring wounds faster, researchers have found. The discovery could advance research and treatment of psoriasis and other inflammatory diseases.
New research helps address a longstanding question about the inflammatory skin condition psoriasis: Why do skin lesions that have resolved with therapy recur in the same locations after a patient stops using topical steroids?
Compounds derived from fire ant venom can reduce skin thickening and inflammation in a mouse model of psoriasis, Emory and Case Western scientists have shown.
Solenopsins, the main toxic components of fire ant venom, chemically resemble ceramides, which are lipid-like molecules essential for maintaining for the barrier function of the skin. Solenopsin analogs can reduce skin thickening and inflammation in a mouse model of psoriasis, scientists have shown.
Nail pitting is characterized by small indents or depressions on the nail surface. Learn about the causes, symptoms, how it is diagnosed, and treatments.
The more the surface area of the body is covered by psoriasis, the greater the risk of death for the patient suffering from the condition, according to a new analysis. Patients with psoriasis on 10 percent or more of their body are at almost double the risk of death.
Eczema is one of the most common skin conditions in the United States, and research into treatment is ongoing. Learn about using probiotics to treat eczema
